Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) Meeting Abstract


Authors: Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Gerritsen, W. R.; Gurney, H.; Quinn, D. I.; Culine, S.; Sternberg, C. N.; Nam, K.; Frenkl, T. L.; Godwin, J. L.; Bajorin, D. F.; Vaughn, D. J.
Abstract Title: Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
Meeting Title: 44th ESMO Congress (ESMO 2019)
Journal Title: Annals of Oncology
Volume: 30
Issue: Suppl. 5
Meeting Dates: 2019 Sep 27-Oct 1
Meeting Location: Barcelona, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2019-10-01
Start Page: v366
End Page: v367
Language: English
ACCESSION: WOS:000491295502346
PROVIDER: wos
DOI: 10.1093/annonc/mdz249.018
Notes: Meeting Abstract: 919P -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dean Bajorin
    660 Bajorin